<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04392024</url>
  </required_header>
  <id_info>
    <org_study_id>2019-12-020</org_study_id>
    <nct_id>NCT04392024</nct_id>
  </id_info>
  <brief_title>Clinical Outcome of Extended-depth-of-focus Trifocal Intraocualr Lens (Triumf) Implantation</brief_title>
  <official_title>Clinical Outcome of Extended-depth-of-focus Trifocal Intraocualr Lens (Triumf) Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical outcome of extended-depth-of-focus trifocal intraocualr lens (Triumf) implantation
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">January 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uncorrected distant visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Visual acuity at distant with bare eyes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncorrected near visual acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Visual acuity at near with bare eyes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contrast sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Ability to recognize figure or letter at different contrast environment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Vision</measure>
    <time_frame>3 months</time_frame>
    <description>Degree of various symptoms associated with vision</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Triumf</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects who have cataract surgery with Triumf IOL</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Triumf</intervention_name>
    <description>Triumf is intraocular lens which offers multifocal vision by extended depth of focus and diffractive optics.</description>
    <arm_group_label>Triumf</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult at the age of 21 or older at the time of the pre-operative examination and
             willing to have surgery on their 2nd eye within 7-28 days of their 1st eye

          2. Age-related cataract

          3. A patient with preoperative corneal astigmatism from IOL Master less than 1 diopters

          4. A patient want presbyopia correction at the same time as cataract surgery

          5. A patient has the visual potential of 20/25 or better in each eye after cataract
             removal and IOL implantation

          6. Written informed consent to surgery and participation in the study

        Exclusion Criteria:

          1. Those with other diseases that can affect capsule stability such as pseudoexoliation
             syndrome, glaucoma, traumatic cataract

          2. Pregnant woman and lactating woman

          3. A patient with history of ocular trauma or ocular surgery (Intraocular surgery,
             refractive surgery, ocular surface surgery) in either eye

          4. A patient with evidence of keratoconus or significant irregular astigmatism on
             pre-operative topography in either eye

          5. If expectations for presbyopia correction are too high

          6. Those who are not able to read and understand the informed consent (illiterate or
             foreigners)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-Young Chung, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae-Young Chung, PhD</last_name>
    <phone>82-2-3410-3548</phone>
    <email>teayoung15.chung@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Hui Lim, PhD</last_name>
    <phone>82-2-3410-3548</phone>
    <email>ldhlse@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae-Young Chung</last_name>
      <phone>+82-10-9933-3563</phone>
      <email>tychung@skku.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>tae-young chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depth and focus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

